A consortium of UK pharmaceutical and equipment manufacturers is building a test facility to prove that tablets can be made continuously, rather than in batches, using an integrated production line that monitors quality in real time. This matters because the UK pharmaceutical industry needs a step-change improvement in manufacturing efficiency to remain competitive. Current tablet production is fragmented and inefficient, with separate steps for granulation, drying, blending, and compression, each requiring its own quality checks. The project aims to improve manufacturing precision, productivity, and mass yield by linking advanced equipment with process measurement, control, and information management into a single data acquisition platform. If successful, the work will produce an optimised integration strategy, performance benchmarks, and a de-risked design for a full-scale commercial plant. The concept factory of the future for continuous oral solid dosage manufacture could lower capital costs and speed up production, making the UK supply chain for tablets more resilient and cost-effective. Peripheral work will also deliver a proof-of-concept continuous tablet coater and a continuous powder blender to match the new line.
View original technical description
In order to underpin the competitiveness of the UK pharmaceutical industry, a step change improvement in manufacturing efficiency is needed. This project aims to deliver this for production of the largest proportion of dosage forms (tablets). The efficiency gains are targeted at improved manufacturing precision, improved productivity and improved mass yield, and will be deliverable at approximately 70% of the capital cost of conventional technology. In developing this capability, significant technical knowledge to be delivered which will enhance the offering of the equipment manufacturers who are part of our consortium. The project will use advanced manufacturing equipment, process measurement, control and information management to deliver the claimed benefits. Previous work has been fragmented; this project will deliver an integrated advanced manufacturing / product release data acquisition platform. It is proposed to set up and use test facilities to prove the feasibility of the required manufacturing platform, enabling the optimal design of a commercial plant capable of making saleable product. The key deliverables are (i) an optimised integration strategy, (ii) performance benchmarks, (iii) a de-risked design for a full scale integrated facility, and (iv) data to demonstrate design effectiveness to key stakeholders including regulatory agencies. The process uses continuous twin screw granulation, fluid bed drying, inline blending and tablet compression, whilst PAT instruments along with standard process parameters such as temperature, pressure and work input are used to monitor the stability and control the process Product release is focused around real time continuous process monitoring and control. It is based on an understanding of the process acquired during the experimental trials following DfM/QbD principles. A concept factory of the future will be designed for the layout and operation of continuous OSD pharmaceutical manufacture. Peripheral work to the above this project will also is deliver a POC continuous tablet coater that coats at a rate to compliment the continuous trial equipment and a continuous powder blender.
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know